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Type: Systematic Review 1 
The Long and Winding Road: A Systematic Literature Review Conceptualising 2 
Pathways for Hypertension Care and Control in Low- And Middle-Income Countries 3 
Abstract 4 
Background: Hypertension control is poor everywhere, especially in low- and middle-income 5 
countries (LMICs). An effective response requires understanding factors acting at each stage 6 
on the patients’ pathway through the health system from entry or first contact with the health 7 
system, through to treatment initiation and follow up. This systematic review aimed to identify 8 
barriers to and facilitators of hypertension control along this pathway and, respectively, ways 9 
to overcome or strengthen them.  10 
 11 
Methods: MEDLINE, EMBASE, Global Health, CINAHL Plus, and Africa-Wide Information 12 
(1980-April 2019) were searched for studies of hypertensive adults in LMICs reporting details 13 
of at least two adequately described health system contacts. Data were extracted and analysed 14 
by two reviewers. Themes were developed using NVivo in patient-related (socio-demographic, 15 
knowledge and health beliefs, health status and co-morbidities, trade-offs), social (social 16 
relationships and traditions) and health system domains (resources and processes). 17 
PROSPERO reregistration: CRD42017074786. Results are reported according to PRISMA 18 
guidelines. 19 
 20 
Results: From 2,584 identified records, 30 were included in the narrative synthesis. At entry, 21 
‘health systems resources and processes’ and ‘knowledge and beliefs about hypertension’ 22 
dominated while ‘social relations and traditions’ and ‘comorbidities’ assume greater 23 
importance subsequently, with patients making ‘trade-offs’ with family priorities during follow 24 
up. Socio-demographic factors play a role, but to a lesser extent than other factors. Context 25 
matters.  26 
 27 
Conclusion and implications: Understanding the changing barriers to hypertension control 28 
along the patient journey is necessary to develop a comprehensive and efficient response to 29 






Hypertension is the leading preventable cause of illness and premature death worldwide 1. It is 4 
easily diagnosed and can be controlled with relatively simple interventions. Yet it is often 5 
unrecognised.  When diagnosed, it requires life-long management and patients may be unaware 6 
of the need for continuous monitoring and adherence to treatment, which can be difficult to 7 
achieve. Moreover, while diagnosis and initiation of medication usually takes place in primary 8 
care, its management involves all levels of the health system, with referral to specialists if 9 
certain complications arise. Interventions to improve care have achieved modest results, and 10 
control remains surprisingly poor in countries at of all income levels 2. It is increasingly 11 
recognised that to be effective, responses must cover the entire patient pathway, from initial 12 
diagnosis through to long term treatment and, hopefully, control.  13 
 14 
Conceptualisation of Patient Pathway 15 
Clinical guidelines typically portray the patient pathway as a linear process from diagnosis and 16 
initiation of medication to follow-up. Yet many journeys are much more complex, especially 17 
as several attempts may be needed to achieve initial control, and as hypertension is increasingly 18 
only one of several conditions affecting the patient. Figure 1 presents some archetypal 19 
pathways applicable to hypertension, and non-communicable disease in general. Which one a 20 
given patient will follow depends not only on their clinical condition but also their socio-21 
economic characteristics, preferences, health beliefs, and features of the health system.  22 
 23 
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Many existing guidelines divide the pathway into stages before and after initiation of treatment 1 
(‘after’ often being defined in diverse ways). They also assume, often implicitly, that once the 2 
patient is in the system, their growing familiarity with both it and their condition means that 3 
the barriers diminish. Few consider the barriers and enablers that act throughout their journey. 4 
Nor do they consider, in any detail, that the patient can interrupt, terminate or re-enter treatment 5 
at any point. Their decision to continue with treatment or not is shaped by a complex mix of 6 
knowledge, preferences, and judgements. Importantly, the factors triggering these decisions 7 
can accumulate, for example when patients face repeated long clinic waits or medicines 8 
shortages and in response seek alternative, less effective forms of care.  9 
This review seeks to synthesise the empirical evidence on what hampers or facilitates the 10 
patient at each stage along the pathway from entry to the health system to achieving 11 




The study protocol uses the Preferred Reporting Items for Systematic Reviews and Meta-16 
Analyses (PRISMA) guidelines and was registered with the International Prospective Register 17 
of Systematic Reviews (PROSPERO: CRD42017074786)3. 18 
 19 
Research Questions 20 
1. How do patients with hypertension move through the health care system, over time and 21 
across different levels and types of care?  22 
2. What are the barriers and enabling factors at each stage of the patient pathway? Which 23 
relate to the health system and which to patient characteristics and their families and social 24 
networks, and how?  25 
3. How can the patient be helped to navigate the pathway successfully?  26 
 27 
Initially, we also sought evidence on how different pathways relate to health outcomes but the 28 
necessary literature was lacking. 29 
 30 
Key Concepts and Assumptions 31 
A Health system comprises “all organizations, people, [resources] and actions whose primary 32 
intent is to promote, restore or maintain health [at the individual or population level]” 4 Both 33 
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supply-side factors (health systems structures and processes) and demand-side factors (patient 1 
choices) influence patient progression. 2 
 3 
Pathway is understood as the patient’s progression through the health system, with the intended 4 
destination being control of hypertension without side effects and avoidance of complications.  5 
 6 
Point of contact is where the patient interacts with the health system or alternative providers.  7 
We conceptualise the patient pathway as having three distinct stages, which we used to 8 
categorise the studies we included, while noting, as above, that the journey is often non-linear. 9 
The first is the initial contact with the health system (entry), perhaps associated with symptoms 10 
that may or may not be related to the diagnosis, and any decision to seek care. This includes 11 
all studies that describe diagnosis (either in a facility or during a community-based screening 12 
programme). The second, treatment initiation, begins with the first prescription and ends with 13 
being established on treatment. For those identified during community screening events, this 14 
stage also includes the moment when they contacted the formal health system and were 15 
provided with care (medicine and advice about nutritional or life-style changes), and not simply 16 
when they were diagnosed. This stage may include a referral to another level of the health 17 
system. The third is long-term management, when the patient has become established on 18 
treatment and they should be receiving follow-up by a designated provider but also including 19 
further referral, and departure and re-entry into the system (for the existing or new condition). 20 
There was, however, a fourth set of studies that do not fall within these stages but instead 21 
discuss pathways overall or in general. The distinction between stages allows us to identify 22 
common pathways through the system but overlaps between stages were common.  23 
 24 
Inclusion and Exclusion Criteria 25 
The review included studies:  26 
• of adults with hypertension (SBP>140 mmHg +/or DBP>90 mmHg) 27 
• from low- and middle-income countries (LMICs) 28 
• including at least two reported contacts with the system or data gathered over a period 29 
when more than one contact with the health system was anticipated  30 
• reporting empirical findings studies (qualitative or quantitative) 31 
• of any design 32 




In addition, studies (mainly qualitative) were included if they elicited patient experiences that 2 
span the length of their journey, even if not fully distinguishing stages of treatment. These also 3 
included studies where patients followed unconventional routes, including self-treatment. It 4 
excluded studies: 5 
• of subjects under 18 years, or not having hypertension 6 
• of patients with pregnancy induced or secondary hypertension 7 
• from high-income countries or conducted before 1980.  8 
• including data on only one contact and no information on subsequent stages (studies 9 
that asked patients to recall previous treatment stages were also excluded) 10 
• not distinguishing clearly between any stages of treatment. 11 
 12 
Search Strategy 13 
The search was conducted by RB in 5 databases; MEDLINE, EMBASE, Global Health, 14 
CINAHL Plus, and Africa-Wide Information, for all relevant articles published after 1980 until 15 
12 April 2019. A combination of key words, phrases, and medical subject headings (MeSH) 16 
for the main concepts; ‘low and middle income countries’, ‘hypertension’, ‘continuity of care’, 17 
and ‘epidemiological studies’ were used (see Annex for a full search strategy in MEDLINE).  18 
 19 
Extraction and Critical Appraisal for Quality Assessment 20 
Two independent reviewers (RB, EH) reviewed all identified abstracts by title and abstract 21 
against the inclusion criteria. Full texts of those retained were then read by the reviewers. A 22 
third reviewer (DB) adjudicated disagreements on eligibility.  23 
The extraction template contained fields for study objectives, how hypertension was defined, 24 
study design, sample size and socio-demographic description of study population, research 25 
methods, risk of bias, country and health care settings (including level of the health system), 26 
description of each contact along the patient pathway, and barriers and enablers at each stage, 27 
if available. It distinguished the different contacts along the pathway and, where this was not 28 
possible, information on barriers and facilitators related to more than one contact was included. 29 
We critically assessed the quality of included articles using standardised checklists for 30 
observational studies (STROBE), randomised controlled trials (CONSORT), and qualitative 31 
and mixed method research (SRQR) as appropriate 5-7. Articles that met at least 80% of these 32 
standards were categorised as ‘high quality’, ‘moderate quality’ if they met between 60% and 33 
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80% of relevant standards, and ‘low quality’ if they met less than 60%. Of the 30 included 1 
studies, 9 were assessed as high quality, 18 as moderate, and 3 as low quality. Data were 2 
extracted by the two reviewers independently and any differences were resolved by discussion 3 
with the third reviewer. 4 
 5 
Analytical Strategy 6 
We used a mix of inductive and deductive analytical approaches. First, two reviewers 7 
independently thematically coded barriers and enablers of care for each of the stages described 8 
above in NVivo 11.0 (QSR International). Codes were then compared and discussed with the 9 
third reviewer and aggregated into non-exclusive categories (domains). This process of 10 
conceptualisation reflected both groupings of key themes within papers, but also codes on 11 
barriers and enablers identified from the broader literature from health systems, medical 12 
anthropology and sociology. This process was iterative; with coding followed by re-13 
organisation of the codes, assessing their level of importance according to their prevalence and 14 
strength of evidence, followed by a further coding. This ensured that the overarching codes are 15 
distinct and represent a meaningful representation of the key barriers and enablers at different 16 
stages of hypertension care. The final typology consisted of the following six domains, also 17 
represented in Figure 2. 18 
 19 
  20 
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Demographics and socio-economic factors included sex, age, and other individual 5 
characteristics associated with access to and use of health services.  6 
 7 
Health systems resources and processes included availability, accessibility and affordability of 8 
resources, such as health workers, facilities, medicines, and models of care acceptable to 9 
patients. These often assume different degrees of importance during each stage of the pathway 10 
8.  11 
 12 
Patients’ (and families) knowledge and beliefs of hypertension. Studies of medical pluralism 13 
and syncretism find that biomedical and local or folk knowledge and beliefs about illness often 14 
interact, facilitating care or creating barriers to it and to adherence to medication 9-11. These 15 
often reflect how people think about their bodies over the life cycle 12. This domain included 16 
knowledge and beliefs about hypertension and bodies, how these may change over time, and 17 
how these may impact on adherence to formally mandated pathways.  18 
Health status and co-morbidities were particularly helpful in understanding ways in which 19 
multiple co-morbidities complicate patient pathways. Given the largely asymptomatic nature 20 






















treatment at all points of contact. Conversely, entering the health system in a quest for treatment 1 
of co-morbidities was sometimes a trigger to manage asymptomatic hypertension. 2 
 3 
Social relationships and traditions. Drawing on medical anthropology 13-16 and research that 4 
recognises health systems as social institutions 17,18 we identified themes around social 5 
relationships (between the patient and their family, local community; and between the patient 6 
and health staff) impact on the patient pathway. Traditions (the association of particular foods 7 
with social events and stages in the life cycle) were coded under this domain.  8 
Trade-offs related to the pathways. Seeking care in LMICs often comes at a cost, financial or 9 
otherwise, not only for the individual but their family. It often places significant burdens on 10 
family welfare. This domain was concerned with how these broader responsibilities influenced 11 
the pathway. While some studies saw this issue in terms of psychological factors (e.g. 12 
forgetfulness in those with competing duties), others viewed patients as making rational trade-13 
offs as part of their coping strategy and balancing different life and treatment decisions. 14 
Complex trade-offs made during the treatment pathway are increasingly discussed 8.  15 
 16 
Given the nature of the data collected, the variation in terminology, definition of each stage a 17 
narrative synthesis was employed. Findings are structured under the three key treatment stages 18 




Description of Included Studies 23 
The flow chart, from 1,945 abstracts identified by title and abstract to the 30 included in the 24 
final synthesis, is displayed in Figure 3. 25 
 26 
  27 
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  11 
Records identified through database searching 
(n = 2584) 
 
MEDLINE (827), EMBASE (1308), Global Health 
(414), CINAHL-plus & Africa-wide information (35) 
Additional records identified through 
other sources 
(n = 0) 
Records after duplicates removed 
(n = 1945) 
Titles and abstracts 
screened 
(n = 1945) 
Records excluded 
(n = 1743) 
Full-text articles assessed 
for eligibility 
(n = 202) 
Full-text articles excluded, 
with reasons 
(n = 172) 
 
Adherence-only (49), No 
patient pathway (81), 
Intervention too specific 
(12), No barriers or 
facilitators (12), Population 
not hypertensives only 
(12), Conference abstract 
(3), Full text not located (3) 
Studies included in 
qualitative synthesis 
(n = 30) 
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Description of Hypertensive Patients 1 
The studies included, and their main characteristics, are described in Table 1. Most studies 2 
were conducted in East and South-East Asia (China 19-22, Vietnam 23, Malaysia 24, Indonesia 3 
25) or sub-Saharan Africa (Ethiopia 26, Ghana 27-29, Kenya 30-32, Namibia 33, Nigeria 34, Tanzania 4 
35, and Uganda 36); and Egypt 37. 3 studies were in Central and South America (Belize 38, Brazil 5 
39-41, Colombia 42, Mexico 43); 1 in South Asia (India 44) and 1 in the Middle East (Iran 45).  6 
 7 
Eighteen studies were quantitative, 9 qualitative, and 3 used mixed methods. Among the 8 
quantitative studies, there were 8 prospective cohorts 19-21,23,28,35,36,38, three cross-sectional 9 
studies 24,37,39, and one prospective randomised control trial 22. Studies using qualitative 10 
research methods employed a mixture of semi-structured and in-depth interviews, focus group 11 
discussions, and ethnographic investigations into patients’ past experiences in seeking care for 12 
hypertension and or adherence to medication. In longitudinal studies, participants were 13 




Table 1 Barriers and facilitators of patient progression in the health systems 1 
Stage Domain Themes Author and Country 
Entry & diagnosis  Health systems 
resources & processes 
 
- Patients from mass screening do not return 
for confirmation or diagnosis, little routine 
monitoring 
Risso Gill et al., 2015 (Malaysia), Shima et al., 2014 
(Malaysia) 
+ Adequate health systems resources, mass 
screening, routine screening, work-place 
screening 
Risso-Gill et al., 2015 (Malaysia), Nations et al., 2011 
(Brazil), Legido-Quigley et al 2015 (Colombia), Youssef 
and Moubarak, 2002 (Egypt) 
Knowledge and beliefs 
about hypertension 
- Limited information and poor understanding 
of causes, symptoms; feeling well 
Legido Quigley et al., 2015 (Colombia), Naanyu et al 
2016 (Kenya), Risso Gill et al 2015 (Malaysia), Gabert et 
al., 2017 (India) 
+ Having symptoms  Legido Quigley et al., 2015 (Colombia), Risso Gill et al., 
2015 (Malaysia), Shima et al., 2014 (Malaysia) 
Progressing through the 
system: initiation of 




- Poverty, work responsibilities and need to 
balance care needs with other daily needs 
Bovet et al., 2008 (Tanzania), Kotwani et al., 2014 
(Uganda), Naanyu et al., 2016 (Kenya), Rachlis et al., 
2016 (Kenya) 
+ More advanced age Bovet, 2001 (Tanzania), Chung, 2005 (Belize), Kotwani 
et al., 2014 (Uganda), Nguyen et al., 2011 (Vietnam) 
+/- Being employed, higher education, being 
female 
Chung et al., 2005 (Belize), Kotwani et al., 2014 
(Uganda), Naanyu et al., 2016 (Kenya) 
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Health status and co 
morbidity 
- History of other chronic diseases, 
behavioural risk factors, milder hypertension, 
forgetfulness, poor motivation, lack of 
symptoms 
Nguyen et al., 2011 (Vietnam), Rachlis et al., 2016 
(Kenya), Bovet et al., 2008 (Tanzania), Kotwani et al 
(Uganda), Naanyu et al, 2016 (Kenya), Rachlis et al 2016 
(Kenya), Rahmawati & Bajorek, 2015 (Indonesia) 
+ Severe hypertension, current tobacco use, 
higher initial blood pressure, personal history 
of hypertension or CVD, worsening health 
status, being overweight, personal initiative 
Bovet et al., 2008 (Tanzania), Chung et al., 2005 (Belize), 
Nguyen et al., 2011 (Vietnam), Rachlis et al., 2016 
(Kenya), Kotwani et al (Uganda) 
+/- Alcohol use, family history of CVD or 
hypertension, worsening health status/ severe 
hypertension 
Naanyu et al., 2016 (Kenya), Rachlis et al., 2016 





- Costs associated with care and treatment, 
treatment and traditional remedies available 
outside health system, poor quality of care, 
lack of staff and/or specialised treatment, long 
queues, longer distance and higher cost of 
transport, poor linkage following community 
level entry 
Bovet et al., 2008 (Tanzania), Kotwani et al., 2014 
(Uganda), Naanyu et al., 2016 (Kenya), Nguyen et al., 
2011 (Vietnam), Rachlis et al., 2016 (Kenya), Rahmawati 
& Bajorek, 2015 (Indonesia), Risso Gill et al., 2015 
(Malaysia), Shima et al., 2014 (Malaysia), Subramanian 
et al. 2018 (Kenya) 
+ Availability and training of healthcare 
providers, accessible of clinic, Comprehensive 
counselling and appropriate referral 
Nguyen et al., 2011 (Vietnam), Rachlis et al., 2016 
(Kenya), Kotwani et al., 2014 (Uganda) 
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+/- Availability of traditional remedies outside 
the health system 
Naanyu et al., 2016 (Kenya), Rachlis et al., 2016 
(Kenya), Bovet et al., 2008 (Tanzania) 
Knowledge and beliefs 
about hypertension 
- Lack of knowledge and poor understanding 
about hypertension (especially 
symptomlessness), stigma 
Bovet et al., 2008 (Tanzania) Chung et al., 2005, (Belize) 
Kotwani et al., 2014, (Uganda), Naanyu et al., 2016, 
(Kenya) Rahmawati and Bajorek, 2015, (Indonesia), 
Rachlis et al., 2016 (Kenya), Chung et al., 2015 (Belize) 
+ History of hypertension, community 
awareness, sensitisation/ education 
Chung et al., 2015 (Belize), Rachlis et al., 2016 (Kenya) 
Social relations and 
traditions 
- Family responsibilities, fear of being 
screened for stigmatised disease (HIV), lack of 
social or family support, poor relationships 
between patient and health worker 
Kotwani et al., 2014 (Uganda), Naanyu et al., 2016 
(Kenya), Rachlis et al., 2016 (Kenya) 
+ Good provider patient relationships, 
concerns about family responsibilities, peer, 
family and social support  
Rachlis et al., 2016 (Kenya) 
Trade-offs - Balancing care needs with other daily 
demands including work and home 
Rachlis et al., 2016 (Kenya), Naanyu et al., 2016 
(Kenya), Kotwani et al., 2014 (Uganda) 
Follow up stage/ retention 




+ / - Older age, higher education, gender, lower 
socio-economic status    
Harries, 2005 (Ghana), Legido Quigley et al., 2015 
(Colombia), Nashilongo et al., 2017 (Namibia), Nations 
et al., 2011 (Brazil), Rachlis et al., 2016 (Kenya), Ramli 
et al., 2012 (Malaysia), Sarfo et al., 2018 (Ghana), 
14 
 
Youssef & Moubarak, 2002 (Egypt), Wong et al., 2009 
(Hong Kong), Wong et al., 2011 (Hong Kong), Wong et 
al. 2015 (Hong Kong) 
Health status and co-
morbidity 
+/- Comorbidities, Higher blood pressure, 
severity of hypertension 
Atinga et al., 2018 (Ghana), Harries et al., 2005 (Ghana), 
Legido Quigley et al., 2015 (Colombia), Mekonnen et al., 
2017 (Ethiopia), Nashilongo et al., 2017 (Namibia), 
Nations et al., 2011 (Brazil), Nayeri et al., 2015 (Iran), 
Nguyen et al., 2011 (Vietnam), Ramli et al., 2012 
(Malaysia), Wong et al., 2009 (Hong Kong), Wong et al., 
2011 (Hong Kong) 
- Lack of symptoms Nations et al., 2011 (Brazil), Nayeri et al., 2015 (Iran), 
Odusola et al., 2014 (Nigeria), Rahmawati & Bajorek, 
2015 (Indonesia), Youssef and Moubarak, 2002 (Egypt) 
Zhao et al., 2012 (China) 
+ Feeling ill or improving under exercise 
program 





resources & processes 
+/- Costs associated with receiving care and 
medicine 
Emmerick et al., 2017 (Brazil), Legido Quigley et al., 
2015 (Colombia), Mekonnen et al., 2017 (Ethiopia), 
Nations et al., 2011 (Brazil), Odusola et al., 2014 
(Nigeria), Rachlis et al., 2016 (Kenya), Rahmawati & 
Bajorek, 2015 (Indonesia), Wong et al., 2009 (Hong 
Kong), Wong et al., 2015 (Hong Kong), Sarfo et al., 2018 
(Ghana) 
- Complex medication regimes, polypharmacy, 
side effects, use of traditional medicine 
Atinga et al., 2018 (Ghana), Harries et al., 2005 (Ghana), 
Legido Quigley et al., 2015 (Colombia), Nations et al., 
2011 (Brazil), Nayeri et al., 2015 (Iran), Odusola et al., 
2014 (Nigeria), Rachlis et al., 2016 (Kenya), Ramli et al., 
2012 (Malaysia), Risso-Gill et al., 2015 (Malaysia), Sarfo 
et al., 2018 (Ghana), Shima et al., 2014 (Malaysia), 
Youssef & Moubarak, 2002 (Egypt), Wong et al 2009 
(Hong Kong), Wong et al 2015 (Hong Kong), Zhao et al., 
2012 (China) 
- Poor quality of service (lack of follow-up, 
tracing of patients, reminders of appointments, 
lack of explanation of treatment, short, 
infrequent visits, slow service and lack of 
appointments, visiting multiple clinics, lack of 
Atinga et al 2018 (Ghana), Gabert et al., 2017 (India), 
Legido Quigley et al., 2015 (Colombia), Nashilongo et 
al., 2017 (Namibia), Nations et al., 2011 (Brazil), Nayeri 
et al., 2015 (Iran), Odusola et al., 2014 (Nigeria), Rachlis 
et al., 2016 (Kenya), Rahmawati & Bajorek, 2015 
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specialist services – especially related to 
patients being seen by general practitioners or 
in accident and emergency settings, lack of 
medicine), distance to the health centre or 
pharmacy.  
(Indonesia), Risso Gill et al., 2015 (Malaysia), Sarfo et 
al., 2018 (Ghana), Shima et al., 2014 (Malaysia), Wong 
et al., 2009 (Hong Kong), Wong et al., 2015 (Hong 
Kong), Zhao et al 2012 (China) 
+ Pharmacist involvement or private sector 
providers, good relationships between 
providers and patients  
Atinga et al., 2018 (Ghana), Gabert et al., 2017 (India), 
Mekonnen et al., 2017 (Ethiopia), Risso Gill et al., 2015 
(Malaysia), Wong et al., 2015 (Hong Kong), Zhao et al., 
2012 (China) 
Knowledge and beliefs 
about hypertension 
+ Good knowledge about hypertension or 
appropriate food to eat and weight loss, 
favourable attitude, faith in treatment or 
orthodox/ biomedicine medicines 
Legido Quigley et al., 2015 (Colombia), Mekonnen et al., 
2017 (Ethiopia), Nayeri et al., 2015 (Iran), Odusola et al., 
2014 (Nigeria), Rachlis et al., 2016 (Kenya), Ramli et al., 
2012 (Malaysia), Youssef & Moubarak, 2002 (Egypt) 
- Poor knowledge about hypertension, Belief 
that the body can recover by itself, that 
medication brings cure, that high blood 
pressure is part of being old or is transient, that 
medicines damage the body. Belief in 
witchcraft and spells 
Atinga et al., 2018 (Ghana), Legido Quigley et al., 2015 
(Colombia), Manto et al 2018, Nayeri et al., 2015 (Iran), 
Odusola et al., 2014 (Nigeria), Rachlis et al., 2016 
(Kenya), Risso Gill et al., 2015 (Malaysia), Shima et al., 




+ pressure of employers to be healthy, personal 
initiative, desire to be healthy   
Legido Quigley et al., 2015 (Colombia), Rachlis et al., 
2016 (Kenya), Rahmawati & Bajorek, 2015 (Indonesia), 
Risso Gill et al., 2015 (Malaysia) 
Trade offs - Pressures of paid work, domestic work, 
unwillingness to defer gratification, low 
motivation or will power 
Nayeri et al. 2015 (Iran), Nashilongo et al., 2017 
(Namibia), Atinga et al.,2018 (Ghana), Legido-Quigley 
et al., 2015 (Colombia) Rachlis et al., 2016 (Kenya), 
Rahmawati and Bajorek, 2015 (Indonesia) 
 + Employer pressures on employee to be 
healthy, personal desire to be health 
Rahmawati and Bajorek, 2015 (Indonesia), Risso-Gill et 
al. 2015 (Malaysia) 
Social relations and 
traditions 
- Lack of social support, misinformation from 
community peers and the media, poor 
relationships and communication between 
patients and health staff, 
Legido Quigley et al., 2015 (Colombia), Nations et al., 
2011 (Brazil), Nayeri et al., 2015 (Iran), Odusola et al., 
2014 (Nigeria), Rachlis et al., 2016 (Kenya), Risso Gill 
et al., 2015 (Malaysia), Rahmawati and Bajorek 2015 
(Indonesia), Shima et al., 2014 (Malaysia) 
+ Supportive relatives and communities, good 
relationships between patients and staff, good 
social reputation of doctor 
Legido- Quigley et al 2015 (Colombia) Nashilongo et al., 
2017 (Namibia), Nayeri et al., 2015 (Iran), Odusola et al., 
2014 (Nigeria), Rachlis et al., 2016 (Kenya), Rahmawati 




+/- Local cultural practices and traditions Atinga et al., 2018 (Ghana), Legido Quigley et al., 2015 
(Colombia), Nayeri et al., 2015 (Iran), Nations et al 
2011., (Brazil), Odusola et al., 2014 (Nigeria), Rachlis et 
al., 2016 (Kenya), Risso Gill et al., 2015 (Malaysia), 
Youssef & Moubarak, 2002 (Egypt) 
Barriers and facilitators not 




+ Older age, being female Ferreira et al., 2015 (Brazil) 
- Poor financial resources Vedanthan et al., 2016 (Kenya) 
Health status and co-
morbidity 
+ being in poor health, being in good health, 
having co-morbidities (cancer, heart disease, 
diabetes) 
Ferreira et al., 2015 (Brazil) 
- Costs of medication, consultation, lab tests, 
transport, difficulty of reaching facility, fear of 
stigma when care is provided by HIV clinic, 
poor timekeeping among staff, stock outs of 
medicines, dislike of nurse led services 
Vedanthan et al., 2016 (Kenya) 
Health systems 
resources & processes 
+ Being covered by health insurance, liking 
nurse led services 
Ferreira et al., 2015 (Brazil), Vedanthan et al., 2016 
(Kenya) 
- No symptoms, belief that symptoms relate to 
witchcraft not hypertension, lack of knowledge 
and community awareness of hypertension 
Vedanthan et al., 2016 (Kenya) 
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Knowledge and beliefs 
about hypertension 
+ Fear of mortality  Vedanthan et al., 2016 (Kenya) 
- Lack of patient satisfaction Vedanthan et al., 2016 (Kenya) 
Social relations and 
traditions 
+ Strong community support, patient 
satisfaction and trust between patients and 
nurses 




Stage 1: Entry to the health system 1 
Most studies examined patients recruited after initial diagnosis in primary care 28,37,38,40,42,46,47, 2 
followed by community screening programmes 23,35,36. Only five described facilitators and 3 
impediments to initiation of contact by patients with the health system 37,40,42,46,47. These fell 4 
into two domains: health systems, and knowledge and beliefs.  5 
 6 
Health systems resources and processes 7 
The most consistent facilitator of diagnosis was the practice of checking blood pressure during 8 
attendance at primary care, which took on particular significance given that hypertension is 9 
largely symptomless until severe, and with any symptoms that are present often non-specific. 10 
37,42,46,47. The widespread failure to do this was linked to the high proportion of patients 11 
diagnosed at an advanced stage with symptoms, 60% of the patients in one Egyptian study 37. 12 
Similar findings were reported from Malaysia 46,47 and Brazil 40. Many countries organise mass 13 
screening events but, as Risso-Gill and colleagues note in Malaysia, few patients subsequently 14 
attend to have their diagnosis confirmed46.  15 
 16 
Knowledge and beliefs 17 
Five studies described how the combination of lack of symptoms and low awareness of its 18 
asymptomatic nature impacts on treatment seeking at the time of initial diagnosis 42,44,46-48. Poor 19 
understanding of the importance of treating hypertension 42,47 also act as barriers.  20 
 21 
Stage 2: Initiation of Treatment 22 
The second stage is when patients have received a diagnosis and been advised to seek care or 23 
have been formally referred into the system from community screening events. Studies 24 
followed patients for 17 months 23 12 months 35, six months 36, and four months 38 while 25 
qualitative studies interviewed patients about their overall experience but did not always 26 
specify which stage of the pathway was involved 25,30,46. Two reported interventions with 27 
components to improve linkage with the health system following screening 35,36. Linkage is a 28 
term originally used in screening for HIV, referring to establishing a link between the patient 29 
and health care. In Tanzania, patients were provided with information about hypertension 35 30 
but it had little impact on health seeking behaviour. In Uganda patients were provided with 31 
information, a voucher to cover transport costs, and a scheduled appointment 36, which was 32 
much more successful. In this stage, barriers and enablers related to demographics, health 33 
21 
 
status, and poorly functioning health systems were most important, although differently in each 1 
context.  2 
 3 
Demographics and socio-economic factors 4 
Four studies reported that older age correlated with greater propensity to seek care after 5 
diagnosis, within a community based programme 23, the public sector 36,38 and in a mix of public 6 
and private systems 35. 7 
 8 
Researchers explored concerns about how costs of treatment affected linking and initial 9 
attendance (see below). The negative impact of financial constraints was described in two 10 
qualitative studies in eastern Kenya 30,48, where they discouraged people from initiating care in 11 
the public sector, with a religious leader noting that “…when somebody is poor it becomes a 12 
silent killer…”.  13 
 14 
In Belize, Uganda, and Vietnam, being female was associated with an increased likelihood of 15 
seeking care after detection during screening events. 23,36,38. However, a qualitative study in 16 
Kenya identified women’s lack of control over financial decision making as a barrier to 17 
accessing care 30. This study also reported men being less likely to seek care unless 18 
experiencing severe symptoms. 19 
 20 
Higher educational and occupational status also facilitated seeking care 36 while in rural 21 
Uganda patients employed in manual labour (e.g. farming) were more likely to link than those 22 
who were unemployed 36.  23 
 24 
Health status and co-morbidities 25 
This domain highlighted the importance of co-morbidities and a family history of coronary 26 
disease. In Vietnam 23 and Kenya 30 behavioural risk factors for cardiovascular disease (CVD) 27 
reduced the probability of seeking care, but in Uganda, alcohol and tobacco use and were 28 
associated with increased likelihood of progressing through the health system 36 and in 29 
Tanzania overweight patients were also more likely to seek care, although the association was 30 
only just significant 35. Having a family history of hypertension was a predictor of linkage to 31 
care in Uganda 36, but not in Vietnam 23. In both Vietnam and Belize, those with a personal 32 
(rather than family) history of CVD were more likely to join a hypertension programme 23,38. 33 
22 
 
Milder hypertension independently predicted not seeking care in a community programme in 1 
Vietnam following diagnosis as did a history of other chronic diseases (explained by these 2 
patients seeking treatment elsewhere) 23.  Finally, worsening health status was considered a 3 
barrier to seeking care in Kenya 30, while severe hypertension facilitated joining a programme 4 
in Vietnam 23. 5 
 6 
The lack of symptoms associated with hypertension was identified as a barrier to seeking care 7 
following diagnosis in five studies 25,30,35,36,48. Naanyu proposed that gender played a role, as 8 
men are reluctant to go to a health centre unless they have a debilitating illness.  One qualitative 9 
study identified forgetfulness and poor motivation as psychological barriers and personal 10 
initiative as a facilitator to linkage 30. 11 
 12 
Health system resources and processes 13 
Inadequacies in the health system were identified as barriers to seeking care at health facilities. 14 
Kenyan clinics lacked staff, equipment, and medication 30. In Malaysia, patients referred for 15 
advice on lifestyle changes were unable to see a dietitian 47. Naanyu and Rachlis both described 16 
how unavailability of medicines in pharmacies and availability of herbal medicine from 17 
traditional healers diverted patients from the Kenyan public health system 30,48. However, in 18 
Tanzania Bovet and colleagues found this to be a very minor problem, as only one of 161 19 
patients sought care from a traditional practitioner 35. However, they did find cost to be a barrier 20 
to continued attendance. In Kenya, costs of diagnosis and treatment, even in relation to public 21 
or subsidised services, pose a significant burden, and may lead to catastrophic expenditure 32. 22 
 23 
In Kenya, the expectation of long queues and poor-quality services was a barrier to linkage48. 24 
Kenyan patients also feared being screened for HIV at facilities and avoided them. 25 
 26 
Distance to a health facility influenced whether patients referred after screening would attend 27 
in rural Uganda 36, Kenya 30, Vietnam 23 and Indonesia 25. This was borne out in qualitative 28 
studies 30 25. In Malaysia, Rahmawati reflects on the difficulties that some elderly patients 29 
might have in getting to mobile clinics.  Yet proximity to health services did not always 30 
improve uptake, Bovet et al report that in Dar Es Salaam, where services are near patients, 31 
uptake of appointments and treatment was very low 35.  32 
23 
 
Knowledge and beliefs 1 
Studies in Kenya and Belize identified poor understanding of hypertension among those not 2 
seeking care after its detection 30,38 coupled with doubt that medicine could alleviate symptoms, 3 
fear of taking it, and belief in witchcraft 30. Several other studies suggest that the lack of 4 
knowledge that hypertension is often symptomless impacts on uptake of services 25,35,36,38,48. 5 
The positive impact of education and awareness raising was described in two studies 30,38, 6 
although this did not reach statistical significance in the study from Belize 38.  7 
 8 
Trade-offs 9 
Competing family and work responsibilities prevented linkage to care in rural Uganda 36, 10 
although transportation costs and difficulties were more frequently implicated. Obligations at 11 
work and home being prioritised against adhering to care were also cited qualitative research 12 
from Kenya, especially if services were of poor quality 30. Naanyu also describes concerns 13 
about being a drain on their own and their families’ resources 48.  14 
 15 
Social relations and traditions 16 
Kotwani and Naanyu described how poor relations between health workers and patients in 17 
Uganda and Kenya were a barrier to seeking care following diagnosis 36,48. In Uganda, fear of 18 
being reprimanded for missing a scheduled appointment was cited by 26% of the 27 people 19 
interviewed who had failed to take up referral following community screening 36. Naanyu’s 20 
study implicated fear of harsh language by health workers 30. Rachlis described how good 21 
provider-patient relations were commonly reported to facilitate access to care following 22 
diagnosis 30. Rachlis also identified lack of partner support and inadequate social support as a 23 
barrier 30. 24 
 25 
Stage 3: Long term management 26 
This stage covers patients who, having been diagnosed, are successfully referred into the 27 
system, received medication or a prescription, or were being followed up (or ‘linked’). Most 28 
studies of this stage of treatment addressed retention within the health system and adherence 29 
to medication (20 of 30) 19-30,33,34,37,40-42,45-47. Barriers and facilitators were identified in all 30 
domains. That relating to health system resources was especially rich, with 21 studies reporting 31 
barriers related to financial, service delivery, medication, and geographical issues.  32 
24 
 
Demographics and socio-economic factors 1 
The evidence is extremely mixed. Four studies, from China and Malaysia, found that adherence 2 
was better among older patients 19-21,24, and women, who were also more likely to attend 3 
appointments 19-21,24,30,40. A qualitative study from Brazil attributed lower adherence and 4 
attendances by men to a macho culture 40, although another from Kenya reported how poor 5 
women had to prioritise domestic commitments and other calls on their finances 30. The 6 
association with education varied 28,37. The Brazilian study identified financial hardship as a 7 
barrier, with poorer patients less likely to seek continuing care after diagnosis or to use cheap 8 
proprietary remedies 40. In Malaysia, as before, ethnic differences were reported, with those of 9 
Malay or Chinese origin more likely to adhere to medication than those of Indian origin, (1.68 10 
(95% CI: 1.03–2.73) and 2.64 (95% CI: 1.54–4.58 times, respectively) 24. However, studies 11 
from Ghana and Namibia, found no significant association between age, sex, income, 12 
education/literacy, employment status, and adherence and hypertension control 29,33. 13 
 14 
Health status and co-morbidities 15 
The relationship between poor health, or presence of co-morbidities, and effective follow up is 16 
inconclusive. Four reported that patients with fewer or no co-morbidities were less adherent to 17 
treatment and antihypertensive medications 19,20,26,28. In Malaysia, patients who also had 18 
diabetes were less likely to be adherent and have higher blood pressure who did not (OR: 1.74 19 
(1.289- 2.39) 24 and a qualitative study in Colombia reported that some patients with multiple 20 
conditions considered hypertension to be unimportant 42. A qualitative study found that patients 21 
on multiple drug therapies stopped medication if they experienced adverse reactions and as 22 
advised by social networks 27. In Vietnam, the dropout rate was significantly higher among 23 
those with mild than severe hypertension (21.5% and 8.2% respectively, p < 0.01)23. Some 24 
personality types (stressed, strict, irritable, depressive or obsessive) were linked to poor 25 
adherence, including to dietary restrictions, in Iran 45, while a Brazilian study implicated 26 
depression, especially among those who lacked social support and where the service quality 27 
was poor 40. However, a study from Namibia found that patients with HIV/AIDs did not have 28 
lower adherence 33. 29 
 30 
The asymptomatic nature of hypertension was frequently invoked as an explanation for non-31 
adherence 22,25,34,37,40,45. For example, a Chinese study reported how those with uncomplicated 32 
hypertension simply do not feel “sick” 22 while, in Brazil, patients take medication according 33 
25 
 
to how they feel , taking half doses or skipping doses 40. In Iran it was reported that some 1 
symptoms that patients associate with high blood pressure, such as numbness and blurred 2 
vision, increase adherence 45. Finally, Rahmawati describes lack of transport for elderly 3 
patients to mobile clinics as a barrier, although the authors consider that it was not possible to 4 
distinguish whether failure to attend the mobile clinic was due to lack of transport or the 5 
asymptomatic nature of the disease 25. 6 
 7 
Health system resources and processes 8 
Health systems barriers and facilitators to adherence and continuity of care could be found in 9 
all fifteen studies. As this was the richest domain, we sub-divided these factors into those 10 
related to financial, staffing and service delivery, medication, and geographic proximity. 11 
 12 
Financial: Seven studies addressed this factor. In Colombia, barriers were created by gaps in 13 
coverage by the social security system and associated need for payment to doctors 42, while 14 
studies in China and Nigeria link care free at the point of use with better adherence 19,34. Two 15 
noted how those living in rural areas of Brazil and Colombia suffered a double disadvantage, 16 
as they were less likely to be covered by social security and the costs of medicines were higher 17 
40,42. A study of the Brazil’s Farmácia Popular (FP) programme found major increases in 18 
continuity of treatment and adherence to medicines for NCDs when key essential medicines 19 
were provided for free, including through private sector pharmacies, while cost sharing by 20 
patients led to decreases 41. In Ethiopia, adherence to medications was 2 times (AOR = 2.06, 21 
95% CI =1.13, 3.76) higher in respondents who obtain it at low or no cost compared to the rest 22 
26. In Indonesia, free blood pressure checks were considered to facilitate access to care 25. 23 
However, Chinese studies reached different conclusions, with one finding greater adherence 24 
among those receiving public assistance 21 while another found it to be greater among those 25 
paying fees 19. 26 
 27 
In Ghana, in a study where study participants were covered by the insurance scheme and had 28 
guaranteed access to antihypertensive medications from hospital pharmacies, 20% reported 29 
problems in obtaining them and this was a significant predictor or poor hypertension control 30 
(OR 1.24 (1.02±1.49)29. Costs associated with purchasing medication was also cited as a barrier 31 
to care in Kenya 30. 32 
26 
 
Service delivery: Six studies identified factors related to service delivery 22,25,40,42,44-47. The 1 
most consistent finding was that retention of patients and adherence to treatment were better 2 
where health facilities were accessible, with short waiting times, longer duration of 3 
appointments with physicians, and offering care that is perceived to be of higher quality. A 4 
study from Namibia noted that many people were aware when their next appointment is but 5 
not attending it, suggest a lack of ways to track the patients or send reminders, as well as 6 
providing incentives 33. One Chinese study found that an enhanced role for pharmacists 7 
(advising physicians of potential changes in medication and advising patients on adherence and 8 
life style), led to improved adherence 22. Conversely, the perceived lack of physicians, nurses, 9 
supplies and diagnostic equipment, high patient volumes and public providers lacking time to 10 
counsel on mediations and adapting lifestyles, transportation and cost were common barriers 11 
to routine check-ups in primary care facilities, with quality sometimes better than in the private 12 
sector 44. An absence of guidelines for BP measurement is also a supply-side barrier, as are 13 
stock-outs of drugs in public facilities, with patients needing to seek their medication in private 14 
pharmacies, thus incurring costs for travel and medication 44. Long waiting times were 15 
identified as a barrier in seven studies 29,30,34,40,42,44-46. 16 
Counterintuitively, in Ghana, blood pressure control was poorer among those treated at a 17 
tertiary facility in dedicated hypertension clinics, mainly in urban areas (2.47 (1.57±3.87) than 18 
in rural primary healthcare facilities which despite these facilities more accessible; this may be 19 
due to poorer conditions and longer waiting times 29. Longer duration of hypertension diagnosis 20 
also reduced the likelihood of successful control. A complex primary care intervention in 21 
Mexico involving a new cadre of community health workers, supply chain improvements, 22 
active case-finding, and education support for rural doctors did not lead to any significant 23 
improvement in blood pressure control among the population of Chiapas State 43. 24 
 25 
Medication-specific issues: In addition to problems associated with purchasing medication (see 26 
above), four studies reported on availability (or lack thereof) of medicine 30,34,42,45. 27 
Unsurprisingly, all reported lack of access, at health facilities 42, in pharmacies 34, and more 28 
generally 45 as a barrier to adherence.  29 
 30 
Twelve studies associated more complex medication regimes, polypharmacy with lower 31 
adherence 19,21,22,24,28,29,34,40,42,45-47, while six noted the adverse impact of side effects of 32 
medication on adherence 30,34,37,40,45-47, with one study from Malaysia finding that few patients 33 
were warned about them 47. Specifically, unclear or ambiguous explanation of regimens or 34 
27 
 
polypharmacy by providers led to patients stopping or increasing medications (when feeling 1 
better or if concerned about side effects), researching and buying non-prescribed drugs 27.  In 2 
some studies the use of traditional medicine was associated with poor adherence 28,45-47 or 3 
described as an alternative to pharmaceuticals that were expensive or hard to find 42.  4 
 5 
Geographical accessibility: Five studies 19,30,34,42,46 examined the role of proximity to health 6 
facilities. Four reported that patients living far away were less likely to attend but all were 7 
based on qualitative data 30,34,42,46. Other studies found that greater distance from a clinic 34 or 8 
living in a different district than the hospital reduced adherence to medication 19. Support for 9 
costs of transport from family members was reported to facilitate continuity of care in 10 
Colombia 42. 11 
 12 
Knowledge and beliefs 13 
Fourteen studies identified limited knowledge about hypertension and its management as a 14 
barrier to adherence and retention 22,24,26,27,30,33,34,37,40,42,45-47,49, while one study found that 15 
although literacy about antihypertensive medication (as distinct from consequences of 16 
hypertension) was high (83% of patients), there was no significant association with adherence 17 
and attending appointments 33.  18 
 19 
Several themes emerged. One was that hypertension was viewed as a transient problem 30,34,45. 20 
Some Malaysian patients described not taking medication as prescribed because of a belief in 21 
their ability to control their blood pressure with physical activity, diet, and stress management 22 
47. A Chinese study found patients who believed they had been cured 22. In Iran, while some 23 
believed that the body could recover by itself, others believed it was inherited and could not be 24 
treated 45. In Ethiopia, users with a favourable attitude—a possible proxy for trust—about 25 
antihypertensive treatment were ten times (AOR = 9.88, 95% CI =5.34, 18.27) more likely to 26 
be adherent than others 26. 27 
 28 
Another strand reflected broader perceptions of illness and disease. In several countries there 29 
was a belief that long term medication would cause damage to the body, especially the kidneys 30 
49, or side effects 27 while in Egypt 37, adherence was lower in those who believed that they 31 
were generally more likely than others to suffer misfortunes. In Ghana, perceptions that 32 
mainstream drugs were ineffective were associated with interrupting or terminating their 33 
28 
 
treatment and substituting herbal medicines and alternative therapies, including spiritual 1 
healing, prayers, and fasting, seen as protective from witchcraft and spells. The impact of these 2 
beliefs was accentuated by the greater ease of obtaining affordable alternative therapies as well 3 
as trusted relationships with native providers and a general belief that ‘medication is 4 
unnecessary because ill-health is an act of God'27. In Colombia and Brazil medication provided 5 
free of charge was sometimes considered inferior to that paid for. However, in Nigeria, faith in 6 
“orthodox medicines” (provided through the health system) was considered to improve 7 
adherence 34.  8 
 9 
One Malaysian study found a small, but statistically significant increase in adherence among 10 
patients with better knowledge of their medication (OR 1.03 – 1.01-1.04, p= 0.001)24, with 11 
similar findings from Egypt 37. However, health workers often lacked educational material and 12 
provided little information to patients 30,46. In Iran, patients identified information in the mass 13 
media as a source of information, although with mixed impact on adherence.  14 
 15 
Trade-offs  16 
Eleven studies addressed trade-offs 25,28,30,34,40,42,45-47. In Iran, patients reported how being busy 17 
working (either outside the home or undertaking childcare) increased the likelihood of 18 
forgetting to take medication 45. However, in Malaysia, pressure from employers to be healthy, 19 
coupled with access to private providers facilitated adherence 46. In Namibia, missing 20 
appointments was very common (75% ever missing a scheduled clinic appointment) and in 21 
60% of cases this was attributed to work commitments, despite being aware of the need for 22 
treatment 33, while in Ghana ‘preoccupation with routine work’ and sustaining livelihoods, 23 
including having to travel away from home, led to de-prioritisation of medication (often framed 24 
as ‘forgetfulness’) 27.  25 
 26 
Seven studies addressed psychological factors 25,28,30,40,42,45,47. An unwillingness to defer 27 
gratification was identified as a barrier to adherence to treatment, including diet in Iran 45. 28 
Three studies identified low motivation or will-power as a barrier to retention 25,30,42 and in 29 
Indonesia the desire to be healthy was associated with enhanced continuity of care 25. 30 
Social relationships and traditions 31 
Eleven studies addressed these issues 25,30,33,34,37,40,42,45-47. Relationships with families and 32 
friends could be either a facilitator or barrier to retention, with poor relationships with family 33 
29 
 
members impacting negatively on adherence 30,34,47; lifestyle modification 46 and retention 30,42 1 
while in several studies family support encouraged adherence 30,34,45,47 and retention in the 2 
system 30,42. For example, support from friends and/or relatives were found to be critical for 3 
adherence through encouragement to take medication and attend follow-up appointments in 4 
Namibia 33. There was little information on the role of local communities, although Shima 5 
reported how Indian patients in Malaysia were influenced by neighbours and friends when 6 
making decisions about adherence 47 while, in Indonesia, peer support was an important 7 
motivator for patients to participate in a community based programme for elderly patients 25.  8 
 9 
Seven studies addressed local cultural practices and traditions 27,30,34,37,42,45,46. Traditional 10 
practices could be a barrier to adherence 34,46 and continuity of care 46. Thus in Ghana, there 11 
could be pressure on from peers, family, and relatives to choose traditional and herbal 12 
medicines, which were perceived to be safer, more effective and cheaper 27. The presence of 13 
fatty food at social events also made lifestyle changes difficult 40,42,45. In Nigeria, attitudes 14 
favouring smaller body size were linked to better adherence while in both Nigeria and Iran, 15 
those with stronger religious beliefs were more likely to be adherent 34,45 but in Brazil fatty or 16 
salty foods are considered to give immense pleasure in later life and so difficult for older 17 
patients to forego 40.  18 
 19 
Where there were positive relationships between health workers, adherence was facilitated. 20 
Having a good patient –provider relationship increased the likelihood of adherence four times 21 
26. In Nigeria, the approachability and social reputation of the doctor was linked to greater 22 
adherence 34. In Indonesia, community health workers encouraged continuity of care in a 23 
community by means of interactive discussions with older patients 25 while in Kenya, good 24 
relationships were identified as increasing retention 30. However, a traditional hierarchical 25 
relationship between health workers and patients in some countries could act as a barrier, as in 26 
Brazil, where doctors adopted an authoritarian approach to older patients, who often lacked 27 
trust in those providing care 40.   28 
 29 
Barriers and Facilitators Not Specific To A Single Domain 30 
Two papers trace the patient’s journey overall 31,39. Most drivers were as in the other papers, 31 
with older women more likely to seek care and limited financial resources impeding continuity 32 
of care, while that those with co-morbidities were more likely to attend appointments. Health 33 
systems related barriers included high costs, medicine stock-outs, inaccessible facilities, and 34 
30 
 
staff absences leading to low levels of satisfaction among patients 31. Care provided by nurses 1 
was considered to be a potential barrier in Kenya, depending on whether patients accepted them 2 




Control of hypertension remains poor everywhere but especially in LMICs 2. This systematic 7 
review examines barriers and facilitators along pathways followed by hypertensive patients — 8 
from first symptoms and entry into the system to treatment initiation and follow-up — that lead 9 
to poor control of their condition. We argue that a better understanding of these issues is an 10 
important step in achieving hypertension control, informing design of interventions. Thirty 11 
papers met the inclusion criteria. A conceptual framework with six domains was used to 12 
analyse the findings. The key findings are summarised in Box 1. 13 
 14 
Box 1 Key findings 15 
• Patients with hypertension confront different barriers and facilitators on their 
journey through the health system, from diagnosis to treatment initiation to 
maintenance; 
• The effects of barriers accumulate along the patient pathway and characteristics of 
the health system can reinforce or mitigate them; 
• Knowledge and beliefs about hypertension are important at entry in the system but 
social relationships, traditions and presence of comorbidities become more 
important later; 
• Patient pathways are non-linear and are best characterised as continual cycles of 
entry and re-entry into the system, as patients seek to accommodate their priorities 
with respect to health and life in general; 
• More evidence is needed on the ways in which individual-, community- and health 
system-related barriers and facilitators interact, taking account of the patient’s 
perspective and their agency at each stage of the pathway if we are to design 





Several limitations must be acknowledged. The first relates to how access was conceptualised 1 
and what study designs were included. Most studies often reported two points of the care 2 
continuum, typically entry into the system and subsequent retention, and were not designed to 3 
capture intervening barriers and facilitators. Second, even those studies following the patient 4 
along the entire pathway often failed to differentiate the various stages. Third, studies often 5 
take a top-down perspective, defining treatment stages according to a predetermined clinical 6 
pathway or programme intervention, rather than reflecting the perspective of the patients, their 7 
needs and preferences. This was particularly the case for the follow-up stage during which 8 
patients may think their treatment has been completed; thus, the agency of the patients is often 9 
overlooked.  10 
 11 
Despite these limitations, our findings show that different combinations of barriers appear to 12 
matter at each stage of the care pathway. At entry the key barriers and facilitators relate to how 13 
effectively patients are identified and how they learn about their condition (‘health systems 14 
resources and processes’ domain) — through primary health care services and/or community-15 
based screening. The patient’s ‘knowledge and beliefs about hypertension’ domain is also key 16 
at this stage. For example, the asymptomatic nature of hypertension influences how the patient 17 
chooses to manage their condition, as would be expected, given the need for patients to 18 
recognise the importance of seeking care 50.  19 
 20 
As patients move along the care pathway, they face an accumulating range of barriers. At the 21 
treatment (medication) initiation stage, most relate to ‘health systems resources and processes’, 22 
pointing to the importance of a well-functioning health system. Co-morbidities act as a barrier 23 
(with some exceptions) as they complicate treatment. ‘Social relations and traditions’ also 24 
emerge at this stage and remain important in the follow-up stage.  25 
 26 
The largest number of studies address the follow-up/ retention stage, which is where a wide 27 
array of issues come into play. Barriers and facilitators spanned all six domains, but the most 28 
important related to poorly resourced and managed health systems, ‘patient knowledge and 29 
beliefs’ and ‘social networks and relationships’. Patients begin to make conscious ‘trade-offs’ 30 
of continuing treatment against fulfilling family and social roles, starting at the treatment stage 31 




While socio-economic characteristics are often a major issue in studies that examine only one 1 
point of the care pathway, particularly entry, overall they are often mitigated or overcome by 2 
characteristics of the health system and social networks, leading patients to make trade-offs 3 
between continuing treatment and meeting other priorities, such as work and family 4 
commitments. 5 
 6 
Few studies sought to challenge the linearity of the pathway (from diagnosis to effective 7 
control), with the exception of Gabert et al. who present it as a continuous cycle of entry and 8 
re-entry/ remaining in the system 44. Most studies see the pathway as normative and singular, 9 
excluding the possibility of diverse trajectories or incomplete cycles constrained by factors 10 
within and beyond the health system. While the qualitative studies often involve an iterative 11 
analysis demonstrating the complexity of the interactions, this is often done only to interpret 12 
the findings and identify policy implications, rather than being integral to study design.  13 
 14 
Most studies identify independently acting barriers and facilitators of effective care or 15 
hypertension control emerging along the patient pathway, but few explicitly demonstrate how 16 
these distinct factors interact or illustrate in what specific cases or contexts a set of enabling 17 
factors can help to overcome barriers. For example, living close to a health facility could be a 18 
facilitator of treatment, but not if family or social networks discourage access. More 19 
specifically, Atinga et al. argue that factors cannot be viewed as a set of fixed causal sequences, 20 
but rather are interrelated, with each triggering a new cycle of behaviour (causal loops), while 21 
they show that the use of traditional and complementary medicines to treat hypertension could 22 
either result from or lead to perceptions that modern medication is ineffective and inappropriate 23 
27.  24 
 25 
The review demonstrates how social relationships within and outside the health system are 26 
significant independent factors, but also mitigate other factors. Thus, patients observe or 27 
modify their behaviour according to social norms and advice from trusted networks on what is 28 
a serious condition, when to seek modern medicine to treat certain conditions and when to cope 29 
with family/ traditional remedies which often contradict recommended treatment regimens 30 
46,48,51. The relationship between providers and patients—reflecting the formal and informal 31 
treatment traditions—appears to be critical. However, information provided to patients is not 32 
always sufficient and understandable (e.g. on how to take their medication, or what are the 33 




The included studies do not sufficiently capture the patient’s perspective and agency. 2 
Interestingly, while maintaining follow-up is important to clinicians, it may be less so from the 3 
point of view of the patients and their families. They may believe that making contact at the 4 
earlier stages of entry and treatment initiation is more important, while maintaining health 5 
afterwards can be done with their own resources and as time permits given other life 6 
commitments. Furthermore, fundamental beliefs about the nature and progression of disease 7 
and what constitutes a (high quality) treatment are central to care for hypertension, which may 8 
or may not be accepted as a largely asymptomatic condition, as an inherited disease, or as a 9 
part of the natural aging process. These perceptions are nested within a broader set of beliefs 10 
of how to manage life and how to reasonably balance ongoing treatment against other 11 
competing priorities, benefiting not only individuals but their families and social networks. 12 
 13 
The study has important implications for policy. Stage-specific evidence about barriers to 14 
hypertension care that address the complexity of pathways and interplay of factors, can help to 15 
inform better targeted and effective hypertension control, which is consistent with emerging 16 
conceptions of ‘precision public health’ 52,53. While measures suggested include tracking 17 
patients, setting-up a reminder system for clinic appointments 33, there is a recognition that 18 
interventions need to go beyond the health systems, for example to address the multiple 19 
competing demands on patients and their families.  20 
 21 
There is also a need for health providers to adopt more people-centred treatment approaches 22 
that account for patients' beliefs, values and norms in managing their condition, and to engage 23 
with the knowledge, treatment strategies and experience of medication by patients and their 24 
families 54, which has also been called as taking a ‘cultural competence therapeutic approach’ 25 
27. This review is part of a larger project that is consistent with these approaches and sees 26 
patients as active agents, determining how their treatment progresses, and gives them voice 27 
through the opportunities offered by mobile technology 55. Nevertheless, the balance of 28 
evidence suggests that a more comprehensive mix of measures is required: accessible health 29 
systems resources including information adapted to patients, but also addressing the structural 30 
causes of ill health and the trade-offs made. Health systems interventions and policies need to 31 




Ultimately, the question is whether such an approach matters? This review is part of a lengthy 1 
programme of work we have undertaken over several years in which we have argued for such 2 
a patient-centred approach. This included two of the studies cited, in Malaysia and Colombia 3 
42,46. These were used to design complex multi-faceted interventions adapted to each context 4 
and evaluated in a cluster randomised trial that achieved substantially improved control 56.  5 
 6 
In conclusion, this review demonstrated that the patient pathway is influenced by a mix of 7 
individual-, community- and health system-related barriers and facilitators that act at different 8 
stages, often interacting. Many of the included studies were designed to capture some but not 9 
all of these, so the ensuing recommendations rarely reflect their complex interplay. More 10 
studies are needed that can distinguish between stages of care, acknowledge both the 11 
formal/normative and informal treatments and actors with which patients engage, and elucidate 12 
the many interacting factors that shape each patient’s journey. A more realistic 13 
conceptualisation of the patient pathway is important for more targeted policy 14 
recommendations, and our conceptual framework offers a useful tool to for further research on 15 
hypertension and other chronic conditions.  16 
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